Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis

Publication date: April 2018
Source:Oral Oncology, Volume 79
Author(s): Hao Peng, Ling-Long Tang, Bin-Bin Chen, Lei Chen, Wen-Fei Li, Yan-Ping Mao, Xu Liu, Yuan Zhang, Li-Zhi Liu, Li Tian, Ying Guo, Ying Sun, Jun Ma
ObjectivesThis study aimed at identifying the optimal induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated by intensity-modulated radiotherapy.Materials and methodsWe identified eligible patients with newly-diagnosed stage III-IVA NPC (excluding T3N0) between September 2009 and May 2015. Survival outcomes and grade 3–4 toxicities were compared between different IC regimen groups.ResultsIn total, 3738 patients were eligible for this study, with 1572 (42.1%), 1085 (29.0%) and 1081 (28.9%) receiving TPF, PF and TP, respectively. In the whole population, multivariate analysis found that TPF seems to be better than PF and TP. Howerver, subgroup analysis revealed TPF and TP had same effectiveness in patients receiving a cumulative cisplatin dose (CCD) ≥200mg/m² in concurrent chemotherapy, while TPF shows relatively better survival benefit in patients receiving CCD<200mg/m². Grade 3–4 toxicities were similar between TPF and TP groups, but were relatively higher than that in PF group.ConclusionsOur study concluded that induction TP regimen may be enough for patients receiving a CCD≥200mg/m², while TPF may be superior to TP and PF for patients receiving a CCD<200mg/m², although grade 3–4 toxic events were more common but tolerable. Further studies are needed to validate our findings.



http://ift.tt/2HkYJhJ